FDA Issues Risk Warning for Sunscreen Recall in Multiple States
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The U.S. Food and Drug Administration (FDA) has designated a recall of multiple sunscreen products as Class II, the second highest of its three risk categories.
The affected products included popular mineral and organic sunscreens marketed under several brand names and were distributed across New Jersey, Florida, and Michigan by Kabana Skin Care, headquartered in Louisville, Colorado.
The recall stemmed from identified deviations from Current Good Manufacturing Practice (cGMP) regulations, according to the agency's enforcement report published July 10.
The FDA classified the action as voluntary and initiated by the firm after the agency identified cGMP deficiencies, including manufacturing or quality control lapses. No public press release had been issued by Kabana Skin Care at the time of reporting.
Newsweek has contacted Kabana Skin Care via email on Friday.
Why It Matters
Class II recalls from the FDA indicate a potential risk to consumer safety where use or exposure to the product may cause temporary or medically reversible adverse health consequences, but serious adverse outcomes are considered unlikely.
These recalls are less serious than Class I events but warrant careful attention for consumers and regulators when they involve widely used over-the-counter products such as sunscreen.
Other recent FDA sunscreen recalls have included incidents of chemical contamination or mislabeling of products, prompting broad national attention to product safety and ingredient integrity. Ensuring adherence to cGMP helps prevent distribution of drugs and cosmetics that may not meet safety or efficacy standards, particularly for items used frequently by vulnerable populations like children or those with sensitive skin. FDA guidance identifies cGMP as the backbone of pharmaceutical and over-the-counter product regulation, safeguarding consumers against potentially hazardous defects.
Stock photo. Two girls are seen walking.
Stock photo. Two girls are seen walking.
Getty Images
What To Know
Recall Details: The recall was initiated voluntarily by Kabana Skin Care on March 12 after the company notified consignees via letter. The FDA classified the recall as Class II on July 10.
The recall was initiated voluntarily by Kabana Skin Care on March 12 after the company notified consignees via letter. The FDA classified the recall as Class II on July 10. Distribution: The affected sunscreens were distributed in New Jersey, Florida, and Michigan.
The affected sunscreens were distributed in New Jersey, Florida, and Michigan. Products Impacted: The recall covered several sunscreen products and lots: B Natural Organics, Organic Sunscreen, Broad Spectrum SPF 30, 25% non-nano Zinc Oxide (lots 410-001, 404-003, 404-001; 204 tubes; Exp 10/31/2027, 04/30/2027) Erin's Faces, Mineral SPF 32 (lot 410-002; 54 tubes) GreenScreen, Kabana Organic Skincare, Broad Spectrum UVA & UVB, SPF 32 (lots 405-002, 405-003; 174 tubes) In Your Face Mineral Tint SPF 31 (lot 408-002; 76 bottles)
The recall covered several sunscreen products and lots: Reason for Recall: The FDA cited deviations from cGMP as the basis for the recall. Good manufacturing practices are essential requirements for assuring product safety and quality throughout manufacture, packaging, and labeling.
The FDA cited deviations from cGMP as the basis for the recall. Good manufacturing practices are essential requirements for assuring product safety and quality throughout manufacture, packaging, and labeling. How Class II Recalls Compare: According to the FDA, Class II recalls apply when "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote." This sits between Class III (least serious) and Class I (most serious) in the FDA's risk hierarchy.
What People Are Saying
FDA's statement on the importance of recalls and cGMP: "FDA is committed to ensuring drugs Americans use are safe and effective. FDA continues to monitor the issue... and is proactively working with companies, when appropriate, to recall products and encourage retailers to remove products from store shelves and online marketplaces when quality issues arise."
What Happens Next?
Consumers in the affected states who purchased any of the recalled sunscreens are advised to discontinue use immediately and consult with the respective brands or Kabana Skin Care for further instructions.
The FDA continues to monitor the recall status while the manufacturer addresses the cGMP-related deficiencies. Further recall terminations or public safety updates will be provided on the FDA website as developments arise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
43 minutes ago
- Associated Press
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 13, 2025-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period. 'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University. Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.' The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period. LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027. The presentation and posters are available on the ' Presentations ' tab of the Amylyx website. Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, The webcast will be archived and available for replay for 90 days following the event. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About the LUCIDITY Trial LUCIDITY ( NCT06747468 ) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit and follow us on LinkedIn and X. For investors, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. View source version on CONTACT: Media Amylyx Media Team (857) 320-6191 [email protected] Lindsey Allen (857) 320-6244 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Amylyx Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 07/13/2025 05:00 PM/DISC: 07/13/2025 05:00 PM
Newsweek
6 hours ago
- Newsweek
Children Consuming Common Sweeteners Face Higher Early Puberty Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Common sweeteners found in foods and drinks may significantly increase the risk of early puberty in children, new research shows. The findings come from a large-scale study that was presented on today at ENDO 2025, the Endocrine Society's annual meeting in San Francisco. Researchers analyzed data from more than 1,400 adolescents and found a strong link between sweetener consumption and central precocious puberty, a condition where puberty begins unusually early—typically before age eight in girls and nine in boys. Central precocious puberty is becoming more common worldwide and can have lasting health consequences, including emotional challenges, shorter adult height and an increased risk of reproductive and metabolic disorders later in life. The increased risk from sweeteners was also notably elevated among teens with specific genetic markers associated with early puberty onset. Close Up Of Girl Drinking Sugary Fizzy Soda From Glass With Straw Close Up Of Girl Drinking Sugary Fizzy Soda From Glass With Straw Daisy-Daisy "This study is one of the first to connect modern dietary habits—specifically sweetener intake—with both genetic factors and early puberty development in a large, real-world cohort," said Yang-Ching Chen, M.D., Ph.D., of Taipei Municipal Wan Fang Hospital and Taipei Medical University in Taipei, Taiwan. The study, part of the ongoing Taiwan Pubertal Longitudinal Study (TPLS) launched in 2018, analyzed data on 1,407 adolescents, of whom 481 were diagnosed with central precocious puberty. Researchers assessed dietary intake using questionnaires and urine testing and measured genetic risk using polygenic risk scores based on 19 genes related to early puberty. The study revealed gender-specific effects of common sweeteners, which include aspartame, sucralose, glycyrrhizin (a compound found in licorice) and added sugars. In girls, consumption of glycyrrhizin, sucralose and added sugars was linked to a higher risk of central precocious puberty. In boys, sucralose stood out as the most significant sweetener associated with early puberty onset. These sweeteners are commonly found in a wide range of everyday foods and drinks, including diet sodas, flavored yogurts, sugar-free gums, protein bars, cereals and even some children's medications. Researchers also found a dose-response relationship: the more sweeteners consumed, the higher the risk. The findings build on Chen's earlier work, which showed that sweeteners can disrupt hormonal regulation and gut microbiota balance. For instance, acesulfame potassium (AceK), another common artificial sweetener, was previously shown to activate brain cell receptors involved in "sweet taste" pathways, increasing the release of puberty-related hormones and stress molecules. Glycyrrhizin was also found to alter gut bacteria and suppress key genes that regulate puberty timing. "This suggests that what children eat and drink, especially products with sweeteners, may have a surprising and powerful impact on their development," Chen said. The findings could have far-reaching implications for dietary guidelines and pediatric care. Chen emphasized that monitoring sweetener intake and considering a child's genetic predisposition may be critical in preventing early puberty and its associated long-term health risks. "These results are directly relevant to families, pediatricians, and public health authorities," Chen said. "They suggest that screening for genetic risk and moderating sweetener intake could help prevent early puberty and its long-term health consequences." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about children's health? Let us know via health@
Yahoo
7 hours ago
- Yahoo
Coca-Cola hit with massive recall as popular product is possibly contaminated: 'All impacted product has been removed from store shelves'
A recall of Coca-Cola-owned Topo Chico mineral water for possible contamination received a Class II risk assignment from the U.S. Food and Drug Administration in June. As Newsweek reported, Coca-Cola issued the limited recall on May 28, and the FDA assigned the risk classification on June 17. The FDA has three recall classes. A Class II recall is a situation in which exposure to the product can "cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The Topo Chico recall occurred because of a potential contamination with Pseudomonas bacteria. This class of bacteria is commonly found in the environment, though a certain type can lead to "infections in the blood, lungs, urinary tract, or other parts of the body after surgery," according to guidance from the Centers for Disease Control and Prevention cited by Newsweek. The recall concerned 241 cases of Topo Chico Mineral Water distributed across five states: Arizona, Louisiana, Nevada, New Mexico, and Texas. Around 40 stores sold the water, including some Costco and Sam's Club locations, Fox Business reported. A spokesperson for Coca-Cola told Newsweek in mid-June that "all impacted product has been removed from store shelves." As of June 25, there were "no illnesses or adverse reactions," reported Food Safety News, though the recall remained active. Consumers who bought the affected 16.9-fluid-ounce bottles were asked to return or discard the product without drinking it. Food recalls are a crucial tool for regulators, companies, and consumers to help protect public health. In the Topo Chico case, Coca-Cola initiated a voluntary product removal in the public's best interest after a distributor informed the corporation about a concern. Viewed broadly, Coca-Cola has a more questionable record regarding its impact on human health and the planet. The company has consistently made the list of World's Worst Plastic Polluters based on audits by the Break Free From Plastic organization. In 2024, Coca-Cola was the largest known producer of branded plastic waste in the world, according to a study reported on by Axios. The production and use of plastic are problematic for various reasons, ranging from microplastic health risks — particularly in plastic-bottled beverages — to the generation of heat-trapping gases that warm the planet. How often do you worry about the quality of your drinking water? Never Sometimes Often Always Click your choice to see results and speak your mind. And, of course, there are complex issues about the nutritional effects of the company's many products. Topo Chico products are packaged in glass and occasionally aluminum, which Coca-Cola correctly touts as more recyclable than plastic. The company also promotes the health benefits of Topo Chico and other products, as well as its overall sustainability goals. Coca-Cola has achieved success in reducing plastic ring packaging, and it has prioritized water replenishment programs to restore usable water to communities. Yet critics have accused Coke of "greenwashing" — making pledges for sustainability efforts that it does not live up to or later retracts, such as when it walked back a commitment to reusable packaging, The Guardian reported. Meanwhile, the complexities of ensuring safe and uncontaminated drinking water are not a problem limited to Coca-Cola — critics have called for improving research and regulation in this area, as well. For consumers concerned about health and the environment, it's important to be aware of and responsive to food recalls, to think critically about companies' health claims and efforts, and to support brands that reduce plastic packaging. To save money while reducing microplastic concerns, consumers can also switch to reusable bottles made of non-plastic materials. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
